Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 15,040 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total transaction of $1,600,707.20. Following the completion of the sale, the director now directly owns 205,171 shares of the company’s stock, valued at approximately $21,836,349.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $127.99 on Friday. The firm’s 50 day simple moving average is $85.54 and its 200 day simple moving average is $76.85. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $129.66. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. The company’s revenue was up 132.9% on a year-over-year basis. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 0.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research reports. Morgan Stanley lifted their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Oppenheimer boosted their price objective on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday. Piper Sandler restated an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research report on Wednesday. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, TD Cowen increased their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.00.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new stake in TransMedics Group in the 1st quarter valued at approximately $30,000. Fidelis Capital Partners LLC bought a new position in shares of TransMedics Group during the 1st quarter worth approximately $35,000. Cutler Group LLC CA raised its holdings in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares during the last quarter. RiverPark Advisors LLC bought a new stake in shares of TransMedics Group in the third quarter worth $60,000. Finally, First Horizon Advisors Inc. boosted its holdings in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.